K Monkhorst
Overview
Explore the profile of K Monkhorst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Wel J, Jebbink M, van den Broek D, Steinbusch L, Theelen W, Ruiter G, et al.
Lung Cancer
. 2024 Nov;
198:107972.
PMID: 39556978
Introduction: Osimertinib resistance inevitably occurs in EGFR mutated NSCLC. We aimed to identify resistance mechanisms (RM) using paired plasma and tumor samples in patients that progressed on 2nd/3rd line osimertinib....
2.
van de Haar J, Roepman P, Andre F, Balmana J, Castro E, Chakravarty D, et al.
Ann Oncol
. 2024 Aug;
35(11):954-967.
PMID: 39112111
Background: Genomic tumour profiling has a crucial role in the management of patients with solid cancers, as it helps selecting and prioritising therapeutic interventions based on prognostic and predictive biomarkers,...
3.
Schouten R, Schouten I, Schuurbiers M, van der Noort V, Damhuis R, van der Heijden E, et al.
PLoS One
. 2024 Jul;
19(7):e0290939.
PMID: 39083479
Introduction: Molecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular profiling in the current standard-of-care (SoC) in a prospective...
4.
Jebbink M, de Langen A, Monkhorst K, Boelens M, van den Broek D, van der Noort V, et al.
JTO Clin Res Rep
. 2023 Apr;
4(4):100481.
PMID: 37035409
Introduction: tyrosine kinase inhibitor improved the survival of patients with metastatic mutation-positive () NSCLC. Despite high response rates, resistance develops inevitably in every patient. In up to 13%, protein overexpression...
5.
Schipper L, Samsom K, Snaebjornsson P, Battaglia T, Bosch L, Lalezari F, et al.
ESMO Open
. 2022 Dec;
7(6):100611.
PMID: 36463731
Background: In ∼3%-5% of patients with metastatic disease, tumor origin remains unknown despite modern imaging techniques and extensive pathology work-up. With long diagnostic delays and limited and ineffective therapy options,...
6.
Castenmiller S, de Groot R, Guislain A, Monkhorst K, Hartemink K, Veenhof A, et al.
Immunooncol Technol
. 2022 Aug;
15:100090.
PMID: 35965844
Background: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Because current treatment regimens show limited success rates, alternative therapeutic approaches are needed. We recently showed that...
7.
Joosten P, de Langen A, van der Noort V, Monkhorst K, Klomp H, Veenhof A, et al.
Lung Cancer
. 2021 Oct;
161:141-151.
PMID: 34600405
Objectives: Patients with advanced stage non-small cell lung cancer (NSCLC) are generally considered incurable. The mainstay of treatment for these patients is systemic therapy. The addition of local treatment, including...
8.
Hopstaken J, de Ruiter J, van Diessen J, Theelen W, Monkhorst K, Hartemink K
Ned Tijdschr Geneeskd
. 2021 Mar;
165.
PMID: 33651512
In this review article we discuss the diagnostic workup and current treatment strategies for non-small cell lung cancer (NSCLC). Anatomical resection and systematic lymph node dissection is the recommended treatment...
9.
Theelen W, Krijgsman O, Monkhorst K, Kuilman T, Peters D, Cornelissen S, et al.
J Transl Med
. 2020 Jul;
18(1):271.
PMID: 32620126
Background: The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis allows us to perform comprehensive immunoprofiling and may assist in dissecting the different components of the immune infiltrate....
10.
Jebbink M, de Langen A, Boelens M, Monkhorst K, Smit E
Cancer Treat Rev
. 2020 Mar;
86:101996.
PMID: 32135383
Since several years targeted therapy has been part of treatment in NSCLC in subsets of patients with specific genetic alterations. One of these alterations involves HER2, a member of the...